Abzena PLC Result of AGM (7821Q)
September 14 2017 - 7:46AM
UK Regulatory
TIDMABZA
RNS Number : 7821Q
Abzena PLC
14 September 2017
Abzena plc
Result of Annual General Meeting
Cambridge, UK, 14 September 2017: Abzena plc (AIM: ABZA,
'Abzena' or the 'Group'), the life sciences group providing
services and technologies to enable better biopharmaceutical
products, announces that at its Annual General Meeting held today
at 10am on the Babraham Research Campus in Cambridge, all
resolutions were duly passed on a show of hands.
Details of the votes received in relation to each of the
resolutions (which are more particularly described in the Notice of
Annual General Meeting dated 28 July 2017) are as follows:
Resol Vote For % In Votes Against % Against Votes % Abstain Total Votes
favour Abstain
------ ------------ -------- -------------- ---------- --------- ---------- ------------
1 153,588,233 100 0 0 0 0 153,588,233
------ ------------ -------- -------------- ---------- --------- ---------- ------------
2 153,588,233 100 0 0 0 0 153,588,233
------ ------------ -------- -------------- ---------- --------- ---------- ------------
3 153,588,233 100 0 0 0 0 153,588,233
------ ------------ -------- -------------- ---------- --------- ---------- ------------
4 153,588,233 100 0 0 0 0 153,588,233
------ ------------ -------- -------------- ---------- --------- ---------- ------------
5 153,588,233 100 0 0 0 0 153,588,233
------ ------------ -------- -------------- ---------- --------- ---------- ------------
6 153,588,233 100 0 0 0 0 153,588,233
------ ------------ -------- -------------- ---------- --------- ---------- ------------
7 153,588,233 100 0 0 0 0 153,588,233
------ ------------ -------- -------------- ---------- --------- ---------- ------------
8 153,588,233 100 0 0 0 0 153,588,233
------ ------------ -------- -------------- ---------- --------- ---------- ------------
Percentage figures have been subject to rounding as considered
appropriate.
The total number of ordinary shares of GBP0.002 each eligible to
be voted at the Annual General Meeting was 213,639,236.
Enquiries:
Abzena plc
John Burt, Chief Executive Officer Julian
Smith, Chief Financial Officer +44 1223 903498
Numis (Nominated Adviser and Broker)
Clare Terlouw / James Black / Paul Gillam +44 20 7260 1000
N+1 Singer (Joint Broker)
Aubrey Powell / Liz Yong +44 20 7496 3000
Instinctif Partners +44 20 7457 2020
Melanie Toyne Sewell / Alex Shaw abzena@instinctif.com
Notes to Editors
About Abzena
Abzena (AIM: ABZA) provides proprietary technologies and
complementary services to enable the development and manufacture of
biopharmaceutical products.
The term 'ABZENA Inside' is used by Abzena to describe products
that have been created using its proprietary technologies and are
being developed by its partners, and include Composite Human
Antibodies(TM) and ThioBridge(TM) Antibody Drug Conjugates (ADCs).
Abzena has the potential to earn future licence fees, milestone
payments and/or royalties on 'ABZENA Inside' products.
Abzena offers the following services and technologies across its
principal sites in Cambridge (UK), San Diego, California (USA) and
Bristol, Pennsylvania (USA):
-- Immunology research studies, including immunogenicity
assessment of candidate biopharmaceutical products;
-- Protein engineering to create humanized antibodies and deimmunised therapeutic proteins;
-- Cell line development for the manufacture of recombinant proteins and antibodies;
-- Contract process development and GMP manufacture of
biopharmaceuticals, including monoclonal antibodies and recombinant
proteins for preclinical and clinical studies;
-- Contract synthetic chemistry and bioconjugation research
services, focused on antibody-drug conjugates (ADCs);
-- Proprietary site-specific conjugation technologies and novel payloads for ADC development; and
-- GMP manufacturer of ADC linkers, payloads & combined linker-payloads.
For more information, please see www.abzena.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGSFEFFLFWSELU
(END) Dow Jones Newswires
September 14, 2017 07:46 ET (11:46 GMT)
Abzena (LSE:ABZA)
Historical Stock Chart
From Apr 2024 to May 2024
Abzena (LSE:ABZA)
Historical Stock Chart
From May 2023 to May 2024